Abg-wtt Global Life Science Capital Partners GP LTD
ABG-WTT Global Life Science Capital Partners GP Ltd is a Hong Kong-based private equity investment firm affiliated with Ally Bridge Group, specializing in the life sciences sector. The firm acts as the general partner for ABG-WTT Global Life Science Capital Partners, L.P., investing in growth-stage life sciences companies globally, with a particular focus on healthcare and biotech innovation. The firm was founded in the early 2020s and serves institutional investors and high net worth individuals seeking exposure to transformative healthcare technologies.
Investment Strategy
ABG-WTT Global Life Science Capital Partners GP Ltd pursues an active investment strategy focused on identifying high-growth life science companies, primarily in the healthcare and biotechnology sectors. The firm seeks to invest in companies with disruptive platforms and products, targeting significant value accretion through strategic guidance and access to global networks. Its portfolio includes direct investments in companies developing cutting-edge diagnostics, therapeutics, and medical devices. The firm favors late-stage private placements and select public market opportunities, prioritizing scalability and potential for global impact.
Latest 13F Filing Activity
Abg-wtt Global Life Science Capital Partners GP LTD filed their most recent 13F report on Jun 30, 2025 disclosing 2 equity positions with a total 13F market value of $27M. The fund increased holdings in Rapid Micro Biosystems Inc., Ceribell Inc.. Abg-wtt Global Life Science Capital Partners GP LTD reduced exposure to CG Oncology Inc., Ceribell Inc., Pulmonx Corp. among others.
Top Holdings
Equity Positions (2)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
C CBLL | CERIBELL INC | 76.17% | $20.4M | 1,088,101 | $25.88 | $18.73 | -$522.3K |
R RPID | RAPID MICRO BIOSYSTEMS INC | 23.83% | $6.4M | 1,848,296 | $4.97 | $3.45 | +$1.5M |
Industry Allocation
Investment Team (9)
| Name | Role | Location | |
|---|---|---|---|
 | Principal | San Francisco, CA , United States | |
 | Senior Analyst | New York, NY , United States | |
 | President and Portfolio Manager, Public Equity | Miami, FL , United States | |
S Srishti Kotiyal | Private Equity Associate | New York, NY , United States | |
S Stephen Mallon | Analyst | New York, NY , United States | |
T Tian Sun | Research Analyst | New York, NY , United States | |
E Emily Tai | Analyst | New York, NY , United States | |
P Paresh Kumar | Vice President, Biotech Private Equity | Boston, MA , United States | |
 | Senior Associate | New York, NY , United States |